A categorization of metal anticancer compounds based on their mode of action.
暂无分享,去创建一个
[1] J. Reedijk. Platinum Anticancer Coordination Compounds: Study of DNA Binding Inspires New Drug Design , 2009 .
[2] J. Navarro,et al. Cyclic assemblies formed by metal ions, pyrimidines and isogeometrical heterocycles : DNA binding properties and antitumour activity , 2009 .
[3] P. Sadler,et al. Photoinduced reactions of cis,trans,cis-[Pt(IV)(N3)2(OH)2(NH3)2) with 1-methylimidazole. , 2009, Chemistry.
[4] A. Casini,et al. Emerging protein targets for anticancer metallodrugs: inhibition of thioredoxin reductase and cathepsin B by antitumor ruthenium(II)-arene compounds. , 2008, Journal of medicinal chemistry.
[5] W. Berger,et al. KP1019, A New Redox‐Active Anticancer Agent – Preclinical Development and Results of a Clinical Phase I Study in Tumor Patients , 2008, Chemistry & biodiversity.
[6] Michael J. Rose,et al. Photoactive Ruthenium Nitrosyls: Effects of Light and Potential Application as NO Donors. , 2008, Coordination chemistry reviews.
[7] P. Sadler,et al. Catalytic organometallic anticancer complexes , 2008, Proceedings of the National Academy of Sciences.
[8] Ingo Ott,et al. Cellular Uptake, Cytotoxicity, and Metabolic Profiling of Human Cancer Cells Treated with Ruthenium(II) Polypyridyl Complexes [Ru(bpy)2(NN)]Cl2 with NN=bpy, phen, dpq, dppz, and dppn , 2008, ChemMedChem.
[9] N. Moitessier,et al. A platinum supramolecular square as an effective G-quadruplex binder and telomerase inhibitor. , 2008, Journal of the American Chemical Society.
[10] Michael J. Rose,et al. Sensitization of ruthenium nitrosyls to visible light via direct coordination of the dye resorufin: trackable NO donors for light-triggered NO delivery to cellular targets. , 2008, Journal of the American Chemical Society.
[11] R. Webster,et al. Similar biological activities of two isostructural ruthenium and osmium complexes. , 2008, Chemistry.
[12] B. Keppler,et al. Electron-transfer activated metal-based anticancer drugs , 2008 .
[13] P. Dyson,et al. The "complex-in-a-complex" cations [(acac)2M subset Ru6(p-iPrC6H4Me)6(tpt)2(dhbq)3]6+: A trojan horse for cancer cells. , 2008, Angewandte Chemie.
[14] Long Jiang,et al. Single oxygen-mediated DNA photocleavage of a di-bithiazolyl ruthenium(II) complex [Ru(btz) 2 (dppz)] 2+ , 2008 .
[15] R. Eldik,et al. The reduction of (ImH)[trans-RuIIICl4(dmso)(Im)] under physiological conditions: preferential reaction of the reduced complex with human serum albumin , 2008, JBIC Journal of Biological Inorganic Chemistry.
[16] P. Sadler,et al. New trends for metal complexes with anticancer activity. , 2008, Current opinion in chemical biology.
[17] L. Juillerat-Jeanneret,et al. Ruthenium porphyrin compounds for photodynamic therapy of cancer. , 2008, Journal of medicinal chemistry.
[18] M. Jakupec,et al. Antitumour metal compounds: more than theme and variations. , 2008, Dalton transactions.
[19] P. Dyson. Systematic Design of a Targeted Organometallic Antitumour Drug in Pre-clinical Development , 2007 .
[20] P. Sadler,et al. The design of organometallic ruthenium arene anticancer agents , 2007 .
[21] A. Vessières,et al. Ferrocifens and ferrocifenols as new potential weapons against breast cancer , 2007 .
[22] T. Hambley. Developing new metal-based therapeutics: challenges and opportunities. , 2007, Dalton transactions.
[23] P. Sadler,et al. Using coordination chemistry to design new medicines , 2007 .
[24] J. Navarro,et al. Design and non-covalent DNA binding of platinum(II) metallacalix[4]arenes. , 2007, Chemistry.
[25] B. Kariuki,et al. Dinuclear ruthenium(II) triple-stranded helicates: luminescent supramolecular cylinders that bind and coil DNA and exhibit activity against cancer cell lines. , 2007, Angewandte Chemie.
[26] R. Eldik,et al. Kinetics and mechanism of the reduction of (ImH)[trans-RuCl4(dmso)(Im)] by ascorbic acid in acidic aqueous solution , 2007, JBIC Journal of Biological Inorganic Chemistry.
[27] Stephen J Lippard,et al. Direct cellular responses to platinum-induced DNA damage. , 2007, Chemical reviews.
[28] J. Aldrich-Wright,et al. Chiral Platinum(II) Metallointercalators with Potent in vitro Cytotoxic Activity , 2007, ChemMedChem.
[29] R. Webster,et al. Ruthenium half-sandwich complexes as protein kinase inhibitors: derivatization of the pyridocarbazole pharmacophore ligand. , 2007, Organic & biomolecular chemistry.
[30] F. Avilés,et al. DNA interaction and antiproliferative behavior of the water soluble platinum supramolecular squares [(en)Pt(N-N)]4(NO3)8 (en=ethylenediamine, N-N=4,4'-bipyridine or 1,4-bis(4-pyridyl)tetrafluorobenzene). , 2007, Journal of inorganic biochemistry.
[31] T. Hambley,et al. Studies of a cobalt(III) complex of the MMP inhibitor marimastat: a potential hypoxia-activated prodrug. , 2007, Chemistry.
[32] A. Bergamo,et al. Ruthenium complexes can target determinants of tumour malignancy. , 2007, Dalton transactions.
[33] P. Sadler,et al. Transplatin is cytotoxic when photoactivated: enhanced formation of DNA cross-links. , 2006, Journal of medicinal chemistry.
[34] N. Farrell,et al. A third mode of DNA binding: Phosphate clamps by a polynuclear platinum complex. , 2006, Journal of the American Chemical Society.
[35] P. Dyson,et al. Classical and Non‐Classical Ruthenium‐Based Anticancer Drugs: Towards Targeted Chemotherapy , 2006 .
[36] R. Scopelliti,et al. Development of organometallic ruthenium-arene anticancer drugs that resist hydrolysis. , 2006, Inorganic chemistry.
[37] B. Elias,et al. Photo-reduction of polyazaaromatic Ru(II) complexes by biomolecules and possible applications , 2006 .
[38] P. Dyson,et al. Metal-based antitumour drugs in the post genomic era. , 2006, Dalton transactions.
[39] T. Boulikas,et al. Liposomal oxaliplatin in the treatment of advanced cancer: a phase I study. , 2006, Anticancer research.
[40] N. Metzler‐Nolte,et al. New principles in medicinal organometallic chemistry. , 2006, Angewandte Chemie.
[41] S. Knapp,et al. Ruthenium half-sandwich complexes bound to protein kinase Pim-1. , 2006, Angewandte Chemie.
[42] I. Usón,et al. Molecular recognition of a three-way DNA junction by a metallosupramolecular helicate. , 2006, Angewandte Chemie.
[43] Katherine H Thompson,et al. Metal complexes in medicinal chemistry: new vistas and challenges in drug design. , 2006, Dalton transactions.
[44] N. Farrell,et al. Synthesis, characterization, and cytotoxicity of a novel highly charged trinuclear platinum compound. Enhancement of cellular uptake with charge. , 2005, Inorganic chemistry.
[45] S. Elmroth,et al. Light-induced anticancer activity of [RuCl2(DMSO)4] complexes. , 2005, Journal of medicinal chemistry.
[46] T. Boulikas,et al. Systemic Lipoplatin infusion results in preferential tumor uptake in human studies. , 2005, Anticancer research.
[47] P. Dyson,et al. In vitro and in vivo evaluation of ruthenium(II)-arene PTA complexes. , 2005, Journal of medicinal chemistry.
[48] F. Noor,et al. A cobaltocenium-peptide bioconjugate shows enhanced cellular uptake and directed nuclear delivery. , 2005, Angewandte Chemie.
[49] A. Vessières,et al. Selective estrogen receptor modulators in the ruthenocene series. Synthesis and biological behavior. , 2005, Journal of medicinal chemistry.
[50] N. Farrell,et al. Unique cooperative binding interaction observed between a minor groove binding Pt antitumor agent and Hoechst dye 33258. , 2005, Inorganic chemistry.
[51] K. Szaciłowski,et al. Bioinorganic photochemistry: frontiers and mechanisms. , 2005, Chemical reviews.
[52] C. S. Allardyce,et al. Rational design of platinum(IV) compounds to overcome glutathione-S-transferase mediated drug resistance. , 2005, Journal of the American Chemical Society.
[53] A. Bergamo,et al. Ruthenium antimetastatic agents. , 2004, Current topics in medicinal chemistry.
[54] Colin G. Barry,et al. Platinum-intercalator conjugates: from DNA-targeted cisplatin derivatives to adenine binding complexes as potential modulators of gene regulation. , 2004, Current topics in medicinal chemistry.
[55] M. Jakupec,et al. Gallium in cancer treatment. , 2004, Current topics in medicinal chemistry.
[56] Douglas S. Williams,et al. An organometallic inhibitor for glycogen synthase kinase 3. , 2004, Journal of the American Chemical Society.
[57] A. Mikhailovsky,et al. Photochemical production of nitric oxide via two-photon excitation with NIR light. , 2004, Journal of the American Chemical Society.
[58] M. Jakupec,et al. Synthesis, crystal structure and pH dependent cytotoxicity of (SP-4-2)-bis(2-aminoethanolato-κ2N, O)platinum(II): a representative of novel pH sensitive anticancer platinum complexes , 2004 .
[59] D. Magde,et al. Synthesis and photochemical properties of a novel iron-sulfur-nitrosyl cluster derivatized with the pendant chromophore protoporphyrin IX. , 2004, Inorganic chemistry.
[60] J. Schellens,et al. A Phase I and Pharmacological Study with Imidazolium-trans-DMSO-imidazole-tetrachlororuthenate, a Novel Ruthenium Anticancer Agent , 2004, Clinical Cancer Research.
[61] J. Collins,et al. DNA binding and biological activity of some platinum(II) intercalating compounds containing methyl-substituted 1,10-phenanthrolines. , 2004, Dalton transactions.
[62] S. Lippard,et al. Synthesis, characterization, and cytotoxicity of a series of estrogen-tethered platinum(IV) complexes. , 2004, Chemistry and Biology.
[63] Jim A. Thomas,et al. Kinetically inert transition metal complexes that reversibly bind to DNA. , 2003, Chemical Society reviews.
[64] Y. Sohn,et al. Synthesis, biodistribution and antitumor activity of hematoporphyrin-platinum(II) conjugates. , 2003, Bioorganic & medicinal chemistry.
[65] Jan Reedijk,et al. New clues for platinum antitumor chemistry: Kinetically controlled metal binding to DNA , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[66] P. Sadler,et al. Highly selective binding of organometallic ruthenium ethylenediamine complexes to nucleic acids: novel recognition mechanisms. , 2003, Journal of the American Chemical Society.
[67] P. A. Lay,et al. Copper complexes of non-steroidal anti-inflammatory drugs: an opportunity yet to be realized , 2002 .
[68] M. Dicato,et al. In vitro inhibition of gene transcription by novel photo-activated polyazaaromatic ruthenium(II) complexes. , 2002, Chemical communications.
[69] C. Lottner,et al. Hematoporphyrin-derived soluble porphyrin-platinum conjugates with combined cytotoxic and phototoxic antitumor activity. , 2002, Journal of medicinal chemistry.
[70] C. Lottner,et al. Soluble tetraarylporphyrin-platinum conjugates as cytotoxic and phototoxic antitumor agents. , 2002, Journal of medicinal chemistry.
[71] P. Sadler,et al. Organometallic ruthenium(II) diamine anticancer complexes: arene-nucleobase stacking and stereospecific hydrogen-bonding in guanine adducts. , 2002, Journal of the American Chemical Society.
[72] Jurek Dobrucki,et al. Interaction of oxygen-sensitive luminescent probes Ru(phen)32+ and Ru(bipy)32+ with animal and plant cells in vitro , 2001 .
[73] C. Che,et al. Platinum(II) Complexes of Dipyridophenazine as Metallointercalators for DNA and Potent Cytotoxic Agents against Carcinoma Cell Lines , 1999 .
[74] D. Odom,et al. Recognition and reaction of metallointercalators with DNA. , 1999, Chemical reviews.
[75] M J Clarke,et al. Non-platinum chemotherapeutic metallopharmaceuticals. , 1999, Chemical reviews.
[76] H. R. Palmer,et al. Bis(dialkyl)dithiocarbamato cobalt(III) complexes of bidentate nitrogen mustards: synthesis, reduction chemistry and biological evaluation as hypoxia-selective cytotoxins. , 1998, Anti-cancer drug design.
[77] C. Biot,et al. Synthesis and antimalarial activity in vitro and in vivo of a new ferrocene-chloroquine analogue. , 1997, Journal of medicinal chemistry.
[78] C. Moucheron,et al. Photophysics of Ru(phen)2(PHEHAT)2+: A Novel “Light Switch” for DNA and Photo-oxidant for Mononucleotides , 1997 .
[79] J. Kelly,et al. Ruthenium(II) complexes with 1,4,5,8,9,12-hexaazatriphenylene and 1,4,5,8-tetraazaphenanthrene ligands: Key role played by the photoelectron transfer in DNA cleavage and adduct formation , 1995 .
[80] W. Denny,et al. Hypoxia-selective antitumor agents. 7. Metal complexes of aliphatic mustards as a new class of hypoxia-selective cytotoxins. Synthesis and evaluation of cobalt(III) complexes of bidentate mustards. , 1993, Journal of medicinal chemistry.
[81] W. Eitel. Die nutzbaren Mineralien mit Ausnahme der Erze und Kohlen. Von Br. Dammer. 2. neubearbeitete Auflage. I. Band. Stuttgart 1927. Verlag von F. Enke. XX, 554 S. Mit 66 Abb , 1927 .
[82] J. Reedijk. Metal-Ligand Exchange Kinetics in Platinum and Ruthenium Complexes , 2008 .
[83] L. Juillerat-Jeanneret,et al. Combined arene ruthenium porphyrins as chemotherapeutics and photosensitizers for cancer therapy , 2008, JBIC Journal of Biological Inorganic Chemistry.
[84] K. Flaherty,et al. An organometallic protein kinase inhibitor pharmacologically activates p53 and induces apoptosis in human melanoma cells. , 2007, Cancer research.
[85] A. Vessières,et al. Ferrocene-mediated proton-coupled electron transfer in a series of ferrocifen-type breast-cancer drug candidates. , 2005, Angewandte Chemie.
[86] R. Knuechel,et al. Combined chemotherapeutic and photodynamic treatment on human bladder cells by hematoporphyrin-platinum(II) conjugates. , 2004, Cancer letters.
[87] A. Bergamo,et al. Influence of chemical stability on the activity of the antimetastasis ruthenium compound NAMI-A. , 2002, European journal of cancer.
[88] C. S. Allardyce,et al. [Ru(η6-p-cymene)Cl2(pta)] (pta = 1,3,5-triaza-7-phosphatricyclo- [3.3.1.1]decane): a water soluble compound that exhibits pH dependent DNA binding providing selectivity for diseased cells , 2001 .
[89] W. Denny,et al. Design and synthesis of cobalt(III) nitrogen mustard complexes as hypoxia selective cytotoxins. The X-ray crystal structure of bis(3-chloropentane-2,4-dionato)(RS-N,N′-bis(2-chloroethyl)ethylenediamine)cobalt(III) perchlorate, [Co(Clacac)2(bce)]ClO4 , 1991 .